Sterling Pharma Acquires UK CRO NewChem Technologies

Sterling Pharma Solutions has purchased NewChem Technologies of the United Kingdom, a contract services provider specializing in organic chemistry and serving customers in areas such as pharmaceuticals, diagnostics, and biotechnology. Sterling is known as a global contract development and manufacturing organization, and their network spreads to a manufacturing site in Cramlington, United Kingdom, a recently GMP-licensed dedicated bioconjugation facility in Deeside, and a 111-acre site in Ringaskiddy, Ireland, as per biopharminternational.

The acquisition of NewChem expands Sterling's scientific resources and experience while looking for ways to synthesis clients' chemicals and establish a role in development and scale up. The financial terms of the transaction were not disclosed, but it included all of NewChem's assets and workers. Furthermore, NewChem's founders, Bob Tyson and Bernard Golding, will continue in their roles as site head and science director. The Newcastle location will collaborate with the Sterling facility in Cary, NC, which serves as an early-phase development hub. “Over the last three years, Sterling has grown significantly, both organically and through a global strategy of acquisitions, and this latest deal marks the next step that will help us achieve our aim of becoming the preferred partner and provider of small molecule services to the pharmaceutical industry,” said Kevin Cook, CEO at Sterling,.

“The expertise and experience within the well-respected and talented NewChem team will provide the business with additional capacity to solve complex chemistry challenges. NewChem’s connections with academia is closely aligned with Sterling’s Technology and Innovation Program which sees us work with a number of leading global academic institutions to bring the latest technologies and innovations to our customers.”